Exeltis has received acceptance from the US Food and Drug Administration (FDA) of the filing of Slinda® (4mg Drospirenone-only pill), the novel oral contraceptive developed by the company. The Prescription Drug User Fee Act (PDUFA) date is expected during the 27 May of 2019.
The pharmaceutical group Insud Pharma has just kicked off the second round of its startup programme #CHEMOSTART!, which aims to help get innovative health projects off the ground and offer additional support to projects which are already up and running.
The prestigious scientific journal The Lancet Gastroenterology and Hepatology journal has published the results of the comparative study of pharmacokinetics, efficacy, safety and immunogenicity of bevacizumab biosimilar BEVZ92 in combination with FOLFOX or FOLFIRI, as the first-line treatment for metastatic colorectal cancer versus the original reference product.
Insud Pharma group have once again been rated “very good” in the 2017-2020 edition of the Spanish government’s Profarma Programme, thanks to our contribution to modernising the sector, our commitment to R&D and our clear focus on activities that add value.
The Autonomous University of Madrid (UAM) and the multinational pharmaceutical company Insud Pharma are launching the UAM-Insud Pharma Programme of Innovation Challenges with a Strong Social Impact for biomedical innovation with an open innovation approach that enables the transfer of knowledge through science excellence to overcome some of the specific challenges of our society.
Chemo’s Química Sintética plant garnered awards in the categories of job creation, environmental protection and investment
The RSE Awards seek to reward the commitment of chemical sector companies that form part of the Responsible Care programme to Corporate Social Responsibility and to meeting the United Nations’ Sustainable Development Goals
The finalists in the #Chemostart programme designed by our Group presented their projects to a round table of investors.
We have become increasingly aware in the past few days of the very severe situation in Guatemala following the eruption of the country’s Volcano of Fire. Through our subsidiary Exeltis Guatemala, we wanted to lend our support and help the victims by donating essential medicines to treat the most common conditions in these kinds of disasters.
The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment